Irritable bowel syndrome (IBS) affects a substantial share of the population, but reported prevalence changes considerably with diagnostic criteria, sampling method, country, and measurement year. The figures below show how those differences shape estimates of IBS burden.
Contents
- How common is IBS?
- Why diagnostic criteria change the estimate
- Who is more likely to have IBS?
- IBS subtypes and bowel patterns
- Differences between countries
- Health care use and related conditions
- Costs and broader health-system burden
How common is IBS?
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that about 12% of people in the United States have IBS. The same source says women are up to two times more likely than men to develop IBS, and people younger than age 50 are more likely to develop it than people older than age 50.
Older U.S. administrative statistics provide a different view of the condition’s measured burden. The NIDDK Digestive Diseases Statistics for the United States lists 15.3 million people with IBS in 1998. It also lists 5.9 million IBS prescriptions in 2004, 1.6 million IBS ambulatory care visits in 2009, 280,000 IBS hospitalizations in 2010, and 21 IBS deaths in 2010. These figures are tied to their stated measurement years and should not be read as current estimates.
Global research also produces different prevalence values depending on the diagnostic framework. A 2025 updated systematic review and meta-analysis reported global IBS prevalence of 13.21% when studies used Rome III criteria and 17.14% when they used Rome IV criteria. In studies using probabilistic sampling, the corresponding adjusted estimates were 11.19% for Rome III and 13.28% for Rome IV.
The meta-analysis included 43 studies covering 188,885 participants. Of those studies, 26 used Rome III criteria and 17 used Rome IV criteria. Its review process identified 9,046 database records; 4,464 unique records remained after duplicates were removed, 4,355 studies were excluded during screening, 109 full-text articles were assessed, and 59 additional full-text articles were excluded.
Why diagnostic criteria change the estimate
IBS prevalence is not a single fixed number because the criteria used to classify symptoms affect who is counted. A comparison reported in the British Society of Gastroenterology guidelines found IBS prevalence of 9.2% using Rome III criteria across 53 studies and 400,000 participants. Using Rome IV criteria, the guideline reported prevalence of 3.8% across 6 studies and more than 80,000 individuals.
The Rome Foundation global study likewise found different pooled results depending on both the diagnostic criteria and the way participants were sampled. Across internet-survey countries, pooled IBS prevalence was 10.1% with Rome III and 3.8% with Rome IV. Across household-survey countries, pooled prevalence was 3.5% with Rome III and 1.5% with Rome IV.
These results describe differences in study definitions and recruitment methods, not a change in one person’s symptoms. Comparing IBS statistics is therefore most useful when the criteria, population, and survey method are stated together.
| Measurement setting | Rome III IBS prevalence | Rome IV IBS prevalence |
|---|---|---|
| Global updated meta-analysis | 13.21% | 17.14% |
| Probabilistic-sampling studies | 11.19% | 13.28% |
| Rome Foundation internet countries | 10.1% | 3.8% |
| Rome Foundation household countries | 3.5% | 1.5% |
| British guideline comparison | 9.2% | 3.8% |
Who is more likely to have IBS?
Sex differences appear in several datasets, although the size of the difference varies by criteria and study design. In the 2025 meta-analysis, women had Rome III IBS prevalence of 15.69%, compared with 11.10% in men. Under Rome IV criteria, prevalence was 20.17% in women and 11.45% in men.
The Rome Foundation global study reported higher IBS rates among women in internet-survey countries, with a female-to-male odds ratio of 1.7 under Rome III and 1.7 under Rome IV. The NIDDK summarizes the pattern more broadly by stating that women are up to two times more likely than men to develop IBS.
A nationwide Korean claims analysis identified 2.42 million people with IBS, of whom 58.2% were female. In that study, age- and gender-adjusted IBS prevalence was 5.1% in males and 6.9% in females. These Korean values come from a claims database and represent that study’s population and measurement approach.
Age also matters in the NIDDK description: people younger than age 50 are more likely to develop IBS than people older than age 50. The supplied sources do not provide a further age-by-age percentage breakdown, so the broad age comparison is the appropriate level of precision.
IBS subtypes and bowel patterns
The NIDDK divides IBS into three types based on bowel-movement patterns. IBS-C means that more than one quarter of stools are hard or lumpy and less than one quarter are loose or watery. IBS-D means that more than one quarter are loose or watery and less than one quarter are hard or lumpy. IBS-M means that more than one quarter are hard or lumpy and more than one quarter are loose or watery.
The Rome Foundation global study also reported an IBS-U category in its subtype results. In internet-survey countries, Rome IV cases were distributed as 32.4% IBS-C, 28.7% IBS-D, 32.4% IBS-M, and 6.5% IBS-U. In household-survey countries, the distribution was 37.9% IBS-C, 28.8% IBS-D, 17.2% IBS-M, and 16.1% IBS-U.
| Rome IV subtype distribution | Internet countries | Household countries |
|---|---|---|
| IBS-C | 32.4% | 37.9% |
| IBS-D | 28.7% | 28.8% |
| IBS-M | 32.4% | 17.2% |
| IBS-U | 6.5% | 16.1% |
The subtype figures are proportions of subtype cases in the Rome Foundation study, not percentages of every person in the countries surveyed. They also should not be combined with the NIDDK’s three-type description as though the classification systems were identical.
Differences between countries
The Rome Foundation global study covered 14 internet-survey countries and 9 household-survey countries. Its internet-country sample included 29,606 people, while its household-country sample included 18,949 people.
Among internet-survey countries, reported IBS prevalence ranged from 1.3% in Singapore to 7.6% in Egypt. Among household-survey countries, it ranged from 0.2% in India to 4.6% in Bangladesh. The study therefore shows a wide spread between the lowest and highest country estimates within each survey approach.
The study also reported different average IBS severity scores. In internet-survey countries, the Rome IV average was 250, compared with 191 for Rome III. In household-survey countries, the Rome IV average was 174, compared with 134 for Rome III. These scores are study-reported averages and should be interpreted within the Rome Foundation measurement framework.
South Korea provides another country-specific perspective. The nationwide claims analysis identified 2.42 million IBS patients and found that 98.6% visited outpatient clinics. A further 1.9% were treated upon admission, and 87.6% received a prescription. Because these percentages describe recorded claims, they reflect health-system contact as well as the underlying condition.
Health care use and related conditions
The Korean claims study recorded several conditions occurring alongside IBS. Upper gastrointestinal disease co-occurred in 36.1% of IBS patients, respiratory disease in 12.3%, and musculoskeletal disease in 8.0%. Somatoform disorder co-occurred in 4.3%, while depression or anxiety disorders co-occurred in 3.1%.
These are co-occurrence statistics from one nationwide Korean analysis. They do not establish that IBS caused any of the listed conditions, and they should not be generalized automatically to other countries or health systems.
The French national observational IBS study followed about 30,000 patients. Its design combined a 5-year retrospective period with a 1-year prospective period, providing both a look back at recorded health care use and a forward period of observation. The study’s size and design make it useful for understanding care patterns, while its French setting and observational structure remain important context.
U.S. figures from the NIDDK show how recorded care changed across different years: 5.9 million prescriptions in 2004, 1.6 million ambulatory care visits in 2009, and 280,000 hospitalizations in 2010. These measures count different forms of health-system activity and cannot be added together as a single number of patients.
Costs and broader health-system burden
The Korean nationwide analysis estimated IBS costs at 155 million U.S. dollars. It reported that those costs equaled 0.46% of total national medical expenditure. Both figures belong to the Korean study’s cost definition, currency presentation, and measurement context.
A U.S. managed-care study found that total costs were 51% higher over one year for people with IBS than for non-IBS subjects. Within the IBS group, total costs were 35% higher for people with mild abdominal pain or discomfort, 52% higher for moderate pain or discomfort, and 59% higher for severe pain or discomfort. The pain-severity comparisons show a graded association in that study, but they do not by themselves prove that pain severity caused the cost differences.
Taken together, the statistics show why IBS burden is best described with several measures rather than one headline percentage. Prevalence varies by Rome criteria and sampling method; subtype distributions vary between internet and household surveys; and health-system burden can be expressed through prescriptions, visits, hospitalizations, co-occurring conditions, and costs. Keeping the geography, measurement year, diagnostic framework, and study design attached to each figure makes the comparisons more meaningful.